Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
EWST– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne...
August 7, 2025Earnings
Read more →